JP2008534487A5 - - Google Patents

Download PDF

Info

Publication number
JP2008534487A5
JP2008534487A5 JP2008502504A JP2008502504A JP2008534487A5 JP 2008534487 A5 JP2008534487 A5 JP 2008534487A5 JP 2008502504 A JP2008502504 A JP 2008502504A JP 2008502504 A JP2008502504 A JP 2008502504A JP 2008534487 A5 JP2008534487 A5 JP 2008534487A5
Authority
JP
Japan
Prior art keywords
charged
apoa
lipoprotein
cholesterol
hdl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008502504A
Other languages
English (en)
Japanese (ja)
Other versions
JP5317691B2 (ja
JP2008534487A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2006/000635 external-priority patent/WO2006100567A1/en
Publication of JP2008534487A publication Critical patent/JP2008534487A/ja
Publication of JP2008534487A5 publication Critical patent/JP2008534487A5/ja
Application granted granted Critical
Publication of JP5317691B2 publication Critical patent/JP5317691B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008502504A 2005-03-24 2006-03-23 荷電リポタンパク質複合体およびその使用 Active JP5317691B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66518005P 2005-03-24 2005-03-24
US60/665,180 2005-03-24
PCT/IB2006/000635 WO2006100567A1 (en) 2005-03-24 2006-03-23 Charged lipoprotein complexes and their uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012063853A Division JP5542166B2 (ja) 2005-03-24 2012-03-21 荷電リポタンパク質複合体およびその使用

Publications (3)

Publication Number Publication Date
JP2008534487A JP2008534487A (ja) 2008-08-28
JP2008534487A5 true JP2008534487A5 (cg-RX-API-DMAC7.html) 2012-05-17
JP5317691B2 JP5317691B2 (ja) 2013-10-16

Family

ID=36659702

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008502504A Active JP5317691B2 (ja) 2005-03-24 2006-03-23 荷電リポタンパク質複合体およびその使用
JP2012063853A Active JP5542166B2 (ja) 2005-03-24 2012-03-21 荷電リポタンパク質複合体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012063853A Active JP5542166B2 (ja) 2005-03-24 2012-03-21 荷電リポタンパク質複合体およびその使用

Country Status (19)

Country Link
US (4) US8206750B2 (cg-RX-API-DMAC7.html)
EP (3) EP1871341B8 (cg-RX-API-DMAC7.html)
JP (2) JP5317691B2 (cg-RX-API-DMAC7.html)
KR (4) KR101769191B1 (cg-RX-API-DMAC7.html)
CN (2) CN101170994B (cg-RX-API-DMAC7.html)
AT (1) ATE547094T1 (cg-RX-API-DMAC7.html)
AU (1) AU2006226045B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0607728A2 (cg-RX-API-DMAC7.html)
CA (1) CA2602024C (cg-RX-API-DMAC7.html)
CY (2) CY1112783T1 (cg-RX-API-DMAC7.html)
DK (2) DK2289490T3 (cg-RX-API-DMAC7.html)
ES (2) ES2509216T3 (cg-RX-API-DMAC7.html)
IL (3) IL186169A (cg-RX-API-DMAC7.html)
MX (1) MX2007011851A (cg-RX-API-DMAC7.html)
NZ (2) NZ562346A (cg-RX-API-DMAC7.html)
PL (2) PL1871341T3 (cg-RX-API-DMAC7.html)
PT (2) PT1871341E (cg-RX-API-DMAC7.html)
SI (2) SI2289490T1 (cg-RX-API-DMAC7.html)
WO (1) WO2006100567A1 (cg-RX-API-DMAC7.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
WO2006125304A1 (en) * 2005-05-25 2006-11-30 Liponex, Inc. Pharmaceutical compositions for treating or preventing coronary artery disease
CN101489577B (zh) * 2006-06-01 2013-10-16 蒙特利尔心脏病学研究所 治疗心瓣膜病的方法和化合物
US8044021B2 (en) 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) * 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
CA2780482A1 (en) 2008-11-17 2010-05-10 Anil K. Sood Hdl particles for delivery of nucleic acids
PL2939683T3 (pl) * 2009-02-16 2017-07-31 Cerenis Therapeutics Holding Sa Mimetyki apolipoproteiny A-I
JP2012532919A (ja) 2009-07-16 2012-12-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 治療因子を含むhdlおよび治療における使用
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
US10525152B2 (en) * 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
EP2517013A4 (en) * 2009-12-23 2013-07-17 Artery Therapeutics Inc DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH DEFICIENT REVERSE CHOLESTER INTRANSPORT
US20130197226A1 (en) * 2010-07-28 2013-08-01 Jean-Claude Tardif Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction comprising an apolipoprotein peptide/phospholipid complex
CN103108626A (zh) 2010-08-30 2013-05-15 霍夫曼-拉罗奇有限公司 四连蛋白-载脂蛋白a-i、含有它的脂质颗粒及它的用途
SI2767546T1 (sl) 2011-02-07 2019-03-29 Cerenis Therapeutics Holding Sa Lipoproteinski kompleksi in izdelava ter uporaba le-teh
AU2015271986B2 (en) * 2011-02-07 2018-02-22 Cerenis Therapeutics Holding Sa Lipoprotein complexes and manufacturing and uses thereof
EP2688584A4 (en) * 2011-03-25 2015-05-20 Univ Columbia PEGYLATED HUMAN HDL PARTICLES AND METHOD OF PREPARING THEM
KR20140054115A (ko) * 2011-08-25 2014-05-08 에프. 호프만-라 로슈 아게 단축 테트라넥틴-아포지단백질 a-i 융합 단백질, 그를 함유하는 지질 입자 및 그의 용도
US20160018413A1 (en) * 2013-03-14 2016-01-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of Prognosing Preeclampsia
EP3842443B1 (en) 2013-03-15 2025-02-19 Cerenis Therapeutics Holding SA Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
US9708354B2 (en) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
EP2853259A1 (en) * 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
JP2017515893A (ja) 2014-05-02 2017-06-15 セレニス セラピューティクス ホールディング エスアー Hdl治療マーカー
US20160346221A1 (en) 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
US20170165200A1 (en) * 2015-11-20 2017-06-15 University Of North Texas Health Science Center Composition of lipid-based nanoparticles for small molecules and macromolecules
TW201919686A (zh) * 2017-08-10 2019-06-01 法商塞勒尼斯醫療控股公司 脫輔基子(apomers)
TW201919712A (zh) * 2017-08-10 2019-06-01 法商塞勒尼斯醫療控股公司 運送子(cargomers)
CN110151972A (zh) * 2018-02-11 2019-08-23 中国中医科学院中医基础理论研究所 基于多肽的重组高密度脂蛋白前体及其制备方法与应用
US12220462B1 (en) 2018-02-13 2025-02-11 Abionyx Pharma Sa Complexes for delivery of cyclic dinucleotides
DE202019003092U1 (de) * 2019-07-24 2020-01-17 Ruth-Maria Korth Test zur Bestimmung von Proteophospholipiden und FIDA-Formeln zur Bestimmung von Schutzfaktoren , die mit Substraten auszugleichen sind
JP2023522055A (ja) 2020-04-16 2023-05-26 アビオニクス ファーマ エスエー 腎臓病を治療するためのcer-001療法
JP2023522889A (ja) 2020-04-16 2023-06-01 アビオニクス ファーマ エスエー 脂質結合タンパク質ベースの複合体を使用した、急性病態を治療するための方法
MX2023003877A (es) 2020-10-01 2023-04-18 Abionyx Pharma Sa Composiciones que comprenden complejos basados en proteina de union a lipidos para usarse en el tratamiento de enfermedades oculares.
KR20240018430A (ko) 2021-04-15 2024-02-13 아비오닉스 파마 에스에이 기관 보존 용액에서의 지질 결합 단백질-기반 복합체의 사용
KR102531293B1 (ko) * 2021-12-06 2023-05-16 (주) 멥스젠 신규한 재구축 고밀도 지단백 나노입자
EP4504150A1 (en) 2022-04-06 2025-02-12 Abionyx Pharma SA Methods for treating eye diseases using lipid binding protein-based complexes
CA3247588A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa METHODS FOR TREATING LEUKOCYTOSIS, ENDOTHELIAL DYSFUNCTION AND CARDITIS USING LIPID-BINDING PROTEIN COMPLEXES
WO2023237935A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
CN120344255A (zh) 2022-06-10 2025-07-18 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗过度炎性病症的方法
IL322074A (en) 2023-01-13 2025-09-01 Abionyx Pharma Sa Treatment using a lipid-binding protein molecule
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5052123A (cg-RX-API-DMAC7.html) * 1973-01-18 1975-05-09
US4466958A (en) * 1981-03-18 1984-08-21 Morrison L M Food supplement
JPS59164553A (ja) * 1983-03-08 1984-09-17 Fuji Photo Film Co Ltd カラ−写真感光材料
DE3417696A1 (de) * 1984-05-12 1985-11-14 Robert Bosch Gmbh, 7000 Stuttgart Vorrichtung zum volumetrischen abmessen und abfuellen von fluessigkeitsmengen
US5128318A (en) * 1987-05-20 1992-07-07 The Rogosin Institute Reconstituted HDL particles and uses thereof
GB8712540D0 (en) 1987-05-28 1987-07-01 Ucb Sa Expression of human proapolipoprotein a-i
US5231090A (en) * 1990-07-30 1993-07-27 University Of Miami Treatment for hypercholesterolemia
US5220043A (en) 1991-03-21 1993-06-15 Ohio University Synthesis of D-erythro-sphingomyelins
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
JPH09504517A (ja) 1993-09-27 1997-05-06 スミスクライン・ビーチャム・コーポレイション カンプトテシン処方物
US5746223A (en) * 1996-10-11 1998-05-05 Williams; Kevin Jon Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis
JP3754072B2 (ja) 1994-03-22 2006-03-08 リサーチ・コーポレーション・テクノロジーズ・インコーポレーテッド 摂食抑制ペプチド
US5932536A (en) 1994-06-14 1999-08-03 The Rockefeller University Compositions for neutralization of lipopolysaccharides
US5948756A (en) * 1995-08-31 1999-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Therapeutic lipoprotein compositions
IL120005A (en) * 1997-01-14 2000-08-31 Ramot University Authority Of Pharmaceutical compositions for the treatment of the eye
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) * 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
US6017882A (en) * 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
GB9919713D0 (en) 1999-08-19 1999-10-20 Queen Mary & Westfield College New medical use of high density lipoprotein
US6514523B1 (en) * 2000-02-14 2003-02-04 Ottawa Heart Institute Research Corporation Carrier particles for drug delivery and process for preparation
AU7833601A (en) * 2000-07-31 2002-02-13 Daniel L Sparks Charged lipid compositions and methods for their use
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7217785B2 (en) 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
JP4284177B2 (ja) 2001-08-20 2009-06-24 ツェーエスエル ベリング アーゲー 脳卒中および他の虚血性症状の治療用hdl
EP1438060B1 (en) 2001-09-28 2015-11-11 Esperion Therapeutics Inc. Prevention and treatment of restenosis by local administration of drug
AUPR798901A0 (en) 2001-09-28 2001-10-25 Medvet Science Pty. Ltd. Spheroidal hdl particles with a defined phospholipid composition
US7223726B2 (en) 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
FR2836043B1 (fr) 2002-02-15 2004-06-04 Inst Nat Sante Rech Med Vesicules lipidiques, preparation et utilisations
NZ537006A (en) * 2002-05-17 2008-01-31 Esperion Therapeutics Inc The use of apolipoprotein A-I Milano, for the manufacture ofa composition for treating preventing or reducing ischemic reperfusion injury in a tissue or organ
MXPA04011312A (es) * 2002-05-17 2005-02-14 Esperion Therapeutics Inc Metodo para el tratamiento de desordenes dislipidemicos.
AU2003254202A1 (en) * 2002-07-30 2004-02-16 Esperion Therapeutics, Inc. Methods of using non-human animal apoliprotein a-i protein
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
CN101489577B (zh) * 2006-06-01 2013-10-16 蒙特利尔心脏病学研究所 治疗心瓣膜病的方法和化合物
SI2767546T1 (sl) 2011-02-07 2019-03-29 Cerenis Therapeutics Holding Sa Lipoproteinski kompleksi in izdelava ter uporaba le-teh

Similar Documents

Publication Publication Date Title
JP5317691B2 (ja) 荷電リポタンパク質複合体およびその使用
JP2008534487A5 (cg-RX-API-DMAC7.html)
US7994120B2 (en) Method of treating dyslipidemic disorder
AU2012202223B2 (en) Charged lipoprotein complexes and their uses
HK1155389A (en) Charged lipoprotein complexes and their uses
HK1156840B (en) Charged lipoprotein complexes and their uses
HK1115823B (en) Charged lipoprotein complexes and their uses